Share the Risk not the Channel and Sell, Sell, Sell

by Euan Ramsay on October 23, 2011

Traditionally, companies that supply equipment to scientific researchers have used direct sales to drive adoption and growth. For start-ups this would typically require a partnership with an established entity. But recently a new strategy has emerged where the web is used both to create buzz about a product, and as a channel to convert interest to sales. A great example is Helixis, which in April 2010 was acquired by Illumina for $105M less than three years after the company was founded.

Helixis, led by CEO Alex Dickinson, emerged from the laboratories of Nobel Laureate David Baltimore and Prof. Alex Scherer at Caltech. Financed with a $10M Series A round funded by Domain Associates, Advanced Technology Ventures and Okapi Venture Capital, Helixis sought to democratize DNA analysis by introducing a low-cost, better, faster PCR machine (known as the Pixo and after acquisition as Eco Real-Time PCR). By pricing their instrument at $13,900 compared to the $50,000 cost of the market incumbents, Helixis believed that the centralized PCR machine shared by an average of 10 researchers represented the past, with their product shaping the future – a PCR on every researcher’s bench. Helixis drove sales using an internet-based channel in the US, combined with 22 distribution partners worldwide. Less than 3 years later, and with a total investment of $17.3M, Helixis was acquired by Illumina ($70M upfront + $35M milestone-dependent).

This is a great story. The dream of every entrepreneur and investor. Indeed, this acquisition represented the first exit for Okapi Venture Partners, generating a 6 X ROI in less than 3 years. Clearly, the Eco Real-Time PCR was a disruptive technology in a rapidly growing marketplace. Further, the co-founders were exceptional, and were supported by a stellar board including Illumina CEO Jay Flatley. But what I found most interesting was the sales and marketing strategy.

Helixis adopted a novel sales and marketing strategy validated by NanoDrop, manufacturers of low-volume spectrophotometers, who were acquired by Thermo Fisher Scientific in 2007. NanoDrop used the web as a platform to create awareness and buzz around their product. This strategy drove traffic to their website where potential customers were offered a risk-free 7-day trial, with the company covering the shipping costs within North America.

The concept of try-before-you-buy is not new in the laboratory equipment market. Sales reps often arrange for potential customers to test equipment in situ, with the cost of any necessary consumables covered by the customer. By cutting out the direct sales, NanoDrop controlled the sales and marketing of its product and did not rely on a third-party who may, or may not be motivated to promote and sell their product.

The growth and expansion of social media enabled Helixis to refine NanoDrop’s strategy of web advertising, webinars, blogs and customer discussion forums. In 2009, they brought on advisors to help with the product launch, including Lynne Kielhorn a co-founder of NanoDrop. Xconomy reported in January 2010 that Helixis had more than 150 orders for its product, which was due to ship the following April, the same month that the company was acquired by Ilumina.

I would love to know the conversion rate of trials to sales for the NanoDrop and Helixis, and how it compares to the traditional model. Clearly if you have a disruptive product, web-based sales and marketing works as evidenced by the acquisition of NanoDrop and Helixis.

The advent of social media is a boon to suppliers of laboratory equipment. Scientist by definition develop new techniques and share new knowledge with their peers. Similarly, they rely on their peers to develop and validate new techniques and equipment. Using social media channels to create awareness and also to generate reviews accelerates the buzz around your product. Coupled with web-mediated decreases in the cycle-time from submission to publication of scientific articles in peer-reviewed journals, this offers start-ups in these markets new opportunities to promote their products.

As interest drives traffic to the product website, sharing risk with potential customers through fixed-time trials of equipment, or alternatively offering to analyze samples using the equipment, a tactic used by Vancouver-based Boreal Genomics, is a proven mechanism to secure sales independent of traditional distributions channels that cut into revenue. Just ask the founders and investors of NanoDrop and Helixis.

Have used a web-based sales and marketing strategy? Or are you a rep involved in direct sales? Please join the discussion by leaving a comment below.

  • Share/Bookmark

{ 0 comments }

Debt may be a valuable step to conversion from a non-dilutive funding model to an equity financed start-up

Consider this scenario. You are an entrepreneur with an early-stage venture. Emerging from stealth mode, you make it your mission to speak to as many of the great and the good in the community to lay the groundwork for a future Series A financing. (Un)expectedly, someone immediately recognizes that after implementation of your technology – the world will never be the same.

They want in. And they want in now.

If you take the money now what will you offer in return?

Providing equity in return for seed financing necessitates valuation of the company. Issue stock now at the current valuation and dilution could be exacerbated in a future Series A financing. This provides a dilemma for entrepreneurs of early-stage technology companies, particularly when a significant value bump is anticipated upon completion of defined short-term milestones. Enter an alternative financing option: convertible debt.

Convertible debt (often referred to as convertible notes or loans), is where the company borrows the money with the intention of converting the loan to stock at a later pre-determined time. This option avoids company valuation and is often associated with lower legal fees – good news for early-stage companies.

Where’s the value for investors?

For investors, debt is most likely considered in the above scenario where the desire to invest in the company is balanced with the realization that the company is unlikely to accept the money at the current valuation. The investor is compensated for accepting convertible notes by the provision of discounts, or a warrant.

Discounts enable the debt to be converted to stock at a pre-determined discount at the next financing round. For example, in our scenario, if the seed investor agreed a convertible loan with a discount of 20%, and the Series A stock is valued at $1.00 per share, the debt will be converted to stock at a cost of $0.80 per share. If the loan was for $100,000, the seed investor would be issued 125,000 shares ($100,000 divided by $0.80) representing a value of $125,000.

A warrant is often referred to as a warrant coverage percentage. In contrast to a discount, the compensation percentage is applied to the value of the loan, not to determine the cost of a share. For example, a warrant coverage of 20% on a $100,000 loan would entitle the holder of the convertible notes to receive an additional $20,000 of securities at the next financing representing a total value of $120,000.

Learn more about convertible debt

For a more educated description of discounts, warrants, conversion caps and all things convertible debt, I would direct the reader to the excellent posts herehere and here. Fred Wilson describes why as a VC investor he generally does not favor taking debt in early-stage companies, and also provides an example where convertible debt proved valuable for a late-stage entity.

Debt an option for early-stage biotechnology companies?

For early-stage biotech companies operating capital-efficient models to develop proof-of-principle data and create value, such as the “leverage start-up“, seed financing as convertible debt offers a bridge between non-dilutive funding and Series A financing. This is particularly valuable when covering activities that are not eligible grant expenses, but have an impact on short-term milestones that will significantly increase company valuation.

Have you used convertible debt to finance your early-stage venture? If so, I would love to hear your experience. Please comment below.

  • Share/Bookmark

{ 0 comments }

Crowdfunding for Technology Startups

May 24, 2011

Funding is the lifeblood of all start-ups. You may be fortunate to generate revenue early through sales, but in the capital-intensive, regulation-heavy industries like biotech early funding often has to be secured from other sources. There are many possible avenues for financing, both dilutive and non-dilutive, for example, loans, convertible debt, equity, grants, etc. These are [...]

  • Share/Bookmark
Read the full article →

What’s Happening in Biotech? Use RSS feeds & Twitter to Find the Latest News

May 19, 2011

This post was co-written by James Taylor.
The quantity of information accessible via the web can be overwhelming, but through judicious use of free web-based tools a strategy for managing content can be devised. In our experience, biotech entrepreneurs have been slower to adopt these tools than their high-tech cousins. Therefore, this is the first in [...]

  • Share/Bookmark
Read the full article →

Big Pharma (d)evolution through the lens of Pfizer

March 21, 2011
  • Share/Bookmark
Read the full article →

How Do You Relate a Startup to DeVotchKa?

March 15, 2011

I recently had the pleasure of catching Denver-based band DeVotchKa at the Commodore Ballroom in Vancouver, BC. The grammy-nominated  four piece ensemble were touring to promote their latest album 100 lovers.

Before I joined my co-founders on the startup rollercoaster, I regularly enjoyed live music, particularly up-and-coming British bands that I could see for a fraction [...]

  • Share/Bookmark
Read the full article →

Is a Lack of Diversity Bedeviling Big Pharma?

April 25, 2010

During the southern hemisphere summer of 2007, I was fortunate enough to be living on the Australian island state of Tasmania where I spent four months as a visiting scientist at the University of Tasmania. While I was there, I volunteered to assist a Masters student who was trapping and securing radio collars on Tasmanian [...]

  • Share/Bookmark
Read the full article →

What cost for a cure? 99-cents?

April 18, 2010

Yes We Can.
This now (in)famous mantra was the cornerstone of the successful strategy to elect Barack Obama the 44th President of the United States. It is the “We” in Yes We Can that completed a revolution in U.S. politics that began in 2003 with Howard Dean’s ultimately unsuccessful Presidential campaign, where the low-cost distribution power [...]

  • Share/Bookmark
Read the full article →